Apicidin attenuates memory deficits by reducing the Aβ load in APP / PS1 mice
CNS Neuroscience & Therapeutics · 2023
DOI: 10.1111/cns.14102 ↗Kurz gefasst
Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, 2023. Verfasst von Biao Luo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Neurology, Chongqing, China. Hauptthemen laut MEDLINE: Amyloid beta-Protein Precursor, Alzheimer Disease. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Chongqing.
Abstract (Originalsprache)
Aims
Amyloid beta (Aβ) is an important pathological feature of Alzheimer's disease (AD). A disintegrin and metalloproteinase 10 (ADAM10) can reduce the production of toxic Aβ by activating the nonamyloidogenic pathway of amyloid precursor protein (APP). We previously found that apicidin, which is a histone deacetylase (HDAC) inhibitor, can promote the expression of ADAM10 and reduce the production of Aβ in vitro. This study was designed to determine the potential of apicidin treatment to reverse learning and memory impairments in an AD mouse model and the possible correlation of these effects with ADAM10.
Methods
Nine‐month‐old APP/PS1 mice and C57 mice received intraperitoneal injections of apicidin or vehicle for 2 months. At 11 months of age, we evaluated the memory performance of mice with Morris water maze (MWM) and context fear conditioning tests. The Aβ levels were assessed in mouse brain using the immunohistochemical method and ELISA. The expression of corresponding protein involved in proteolytic processing of APP and the phosphorylation of tau were assessed by Western blotting.
Results
Apicidin reversed the deficits of spatial reference memory and contextual fear memory, attenuated the formation of Aβ‐enriched plaques, and decreased the levels of soluble and insoluble Aβ40/42 in APP/PS1 mice. Moreover, apicidin significantly increased the expression of ADAM10, improved the level of sAPPα, and reduced the production of sAPPβ, but did not affect the levels of phosphorylated tau in APP/PS1 mice.
Conclusion
Apicidin significantly improves the AD symptoms of APP/PS1 mice by regulating the expression of ADAM10, which may contribute to decreasing the levels of Aβ rather than decreasing the phosphorylation of tau.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Neurology, Chongqing, China.
- Department of Health Management, Daping Hospital, Army Medical University, Chongqing, China.
- Department of Neurology, The Ninth People's Hospital of Chongqing, Chongqing, China.
ORCID-Profile: Biao Luo, Xiao-Tong Hu
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Chongqing
Zitieren
APA
Luo, B., Chen, J., Zhou, G. F., Xie, X. Y., Tang, J., Wen, Q. X., Song, L., Xie, S. Q., Long, Y., Chen, G. J., & Hu, X. T. (2023). Apicidin attenuates memory deficits by reducing the Aβ load in APP / PS1 mice. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.14102
Vancouver
Luo B, Chen J, Zhou GF, Xie XY, Tang J, Wen QX, et al. Apicidin attenuates memory deficits by reducing the Aβ load in APP / PS1 mice. CNS Neuroscience & Therapeutics. 2023. doi:10.1111/cns.14102
BibTeX
@article{Luo2023,
author = {Luo, Biao and Chen, Jian and Zhou, Gui-Feng and Xie, Xiao-Yong and Tang, Jing and Wen, Qi-Xin and Song, Li and Xie, Shi-Qi and Long, Yan and Chen, Guo-Jun and Hu, Xiao-Tong},
title = {Apicidin attenuates memory deficits by reducing the Aβ load in APP / PS1 mice},
journal = {CNS Neuroscience & Therapeutics},
year = {2023},
doi = {10.1111/cns.14102}
}
EUVIMED